MARKET NEWS AND UPDATES.
Get notified for Latest News and Market Alerts.
Get notified for Latest News and Market Alerts.
×
CMP as on 23-May-22 15:56
₹ 4,274.95Open
₹ 4,249.10Turnover (lac)
₹ 25,952Prev. Close
₹ 4,249.10Day's Vol (shares)
₹ 6,07,072CMP as on23-May-22 15:33
₹ 4,268.00Open
₹ 4,280.00Turnover (lac)
₹ 516Prev. Close
₹ 4,246.30Day's Vol (shares)
₹ 16,961CMP as on 23-May-22 15:29
₹ 4,273.70Open
₹ 4,258.90Open Interest(Contracts)
₹ 24,31,875VWAP
₹ 4,286.89Day's Vol (shares)
₹ 13,72,375Dr Reddys Laboratories Ltd is quoting at Rs 4312.9, up 1.5% on the day as on 12:44 IST on the NSE. The stock is down 18.19% in last one
Of Rs.30 per share
The drug makers consolidated net profit tumbled 76% to Rs 87.50 crore in 15% increase in revenues to Rs 5436.80 crore in Q4 March 2021
Sales rise 14.98% to Rs 5436.80 crore
Nifty Pharma outperformed by 1.2%, while Nifty Bank and Nifty Financial Services surged by 0.7% and 0.9% respectively.
Single digit growth likely in key metrics versus the year-ago quarter
On NSE, the India VIX index outperformed by soaring 2.1%. Nifty Small-Caps and MidCaps indexes rose between 0.5-0.7%.
For commercialization of Tegoprazan in India and six key emerging markets
Dr Reddys Laboratories Ltd is quoting at Rs 3924.9, down 0.15% on the day as on 13:19 IST on the NSE. The stock tumbled 26.33% in last
At meeting held on 22 April 2022
Per Order for ETF & Mutual Funds Brokerage
Per Order for Delivery, Intraday, F&O, Currency & Commodity
